Massive pulmonary thromboembolism in covid-19: Clinical case report.

Abstract

Introduction: The COVID-19 pandemic has currently demonstrated the importance of aggressive evaluation and management, considering its exposure as a highly transmissible viral disease that has multisystem effects and a high mortality rate. Thus, the diagnosis and treatment of pulmonary embolism are challenging under usual circumstances. Objective: To describe a clinical case of massive pulmonary thromboembolism in covid-19. Case Report: A 42-year-old male patient with a personal pathological history of arterial hypertension with a positive rapid test for SARS COV-2 IGG and IGM. Results: There are an estimated 900,000 cases of venous thromboembolism (VTE) in the United States each year, 150,000 to 250,000 pulmonary embolism (PE)-related hospitalizations, and 60,000 to 100,000 deaths, making it the third most common cause of pulmonary embolism. cardiovascular diseases. Conclusion: Once a pulmonary embolism is diagnosed, risk stratification is necessary to define the appropriate management. Currently available treatments may range from anticoagulation alone, catheter-directed thrombolysis, full-dose systemic thrombolysis, catheter embolectomy, surgical embolectomy, and mechanical circulatory support such as extracorporeal membrane oxygenation (ECMO).